JP2017524372A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017524372A5 JP2017524372A5 JP2017515021A JP2017515021A JP2017524372A5 JP 2017524372 A5 JP2017524372 A5 JP 2017524372A5 JP 2017515021 A JP2017515021 A JP 2017515021A JP 2017515021 A JP2017515021 A JP 2017515021A JP 2017524372 A5 JP2017524372 A5 JP 2017524372A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- tcr
- nos
- isolated
- purified
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 41
- 108091008874 T cell receptors Proteins 0.000 claims 40
- 229920001184 polypeptide Polymers 0.000 claims 18
- 102000004196 processed proteins & peptides Human genes 0.000 claims 18
- 108090000765 processed proteins & peptides Proteins 0.000 claims 18
- 125000003275 alpha amino acid group Chemical group 0.000 claims 17
- 102000004169 proteins and genes Human genes 0.000 claims 17
- 108090000623 proteins and genes Proteins 0.000 claims 17
- 210000004027 cell Anatomy 0.000 claims 12
- 150000007523 nucleic acids Chemical group 0.000 claims 8
- 239000000427 antigen Substances 0.000 claims 7
- 108091007433 antigens Proteins 0.000 claims 7
- 102000036639 antigens Human genes 0.000 claims 7
- 238000003259 recombinant expression Methods 0.000 claims 7
- 239000013604 expression vector Substances 0.000 claims 6
- 108020004707 nucleic acids Proteins 0.000 claims 6
- 102000039446 nucleic acids Human genes 0.000 claims 6
- 239000002773 nucleotide Substances 0.000 claims 6
- 125000003729 nucleotide group Chemical group 0.000 claims 6
- 241000701806 Human papillomavirus Species 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 241000124008 Mammalia Species 0.000 claims 4
- 241000341655 Human papillomavirus type 16 Species 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 208000006994 Precancerous Conditions Diseases 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 101000767631 Human papillomavirus type 16 Protein E7 Proteins 0.000 claims 1
- 208000002471 Penile Neoplasms Diseases 0.000 claims 1
- 208000004354 Vulvar Neoplasms Diseases 0.000 claims 1
- 210000002255 anal canal Anatomy 0.000 claims 1
- 210000003679 cervix uteri Anatomy 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 210000001215 vagina Anatomy 0.000 claims 1
- 239000013598 vector Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462004335P | 2014-05-29 | 2014-05-29 | |
| US62/004,335 | 2014-05-29 | ||
| PCT/US2015/033129 WO2015184228A1 (en) | 2014-05-29 | 2015-05-29 | Anti-human papillomavirus 16 e7 t cell receptors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020127833A Division JP6997267B2 (ja) | 2014-05-29 | 2020-07-29 | 抗ヒトパピローマウイルス１６ ｅ７ ｔ細胞受容体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017524372A JP2017524372A (ja) | 2017-08-31 |
| JP2017524372A5 true JP2017524372A5 (enExample) | 2018-06-28 |
| JP6742991B2 JP6742991B2 (ja) | 2020-08-19 |
Family
ID=53396593
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017515021A Active JP6742991B2 (ja) | 2014-05-29 | 2015-05-29 | 抗ヒトパピローマウイルス１６ ｅ７ ｔ細胞受容体 |
| JP2020127833A Active JP6997267B2 (ja) | 2014-05-29 | 2020-07-29 | 抗ヒトパピローマウイルス１６ ｅ７ ｔ細胞受容体 |
| JP2021203953A Active JP7291196B2 (ja) | 2014-05-29 | 2021-12-16 | 抗ヒトパピローマウイルス１６ ｅ７ ｔ細胞受容体 |
| JP2023091878A Active JP7535158B2 (ja) | 2014-05-29 | 2023-06-02 | 抗ヒトパピローマウイルス１６ ｅ７ ｔ細胞受容体 |
| JP2024126652A Active JP7744479B2 (ja) | 2014-05-29 | 2024-08-02 | 抗ヒトパピローマウイルス１６ ｅ７ ｔ細胞受容体 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020127833A Active JP6997267B2 (ja) | 2014-05-29 | 2020-07-29 | 抗ヒトパピローマウイルス１６ ｅ７ ｔ細胞受容体 |
| JP2021203953A Active JP7291196B2 (ja) | 2014-05-29 | 2021-12-16 | 抗ヒトパピローマウイルス１６ ｅ７ ｔ細胞受容体 |
| JP2023091878A Active JP7535158B2 (ja) | 2014-05-29 | 2023-06-02 | 抗ヒトパピローマウイルス１６ ｅ７ ｔ細胞受容体 |
| JP2024126652A Active JP7744479B2 (ja) | 2014-05-29 | 2024-08-02 | 抗ヒトパピローマウイルス１６ ｅ７ ｔ細胞受容体 |
Country Status (21)
| Country | Link |
|---|---|
| US (4) | US10174098B2 (enExample) |
| EP (2) | EP3689900B1 (enExample) |
| JP (5) | JP6742991B2 (enExample) |
| KR (2) | KR102618267B1 (enExample) |
| CN (2) | CN106661098B (enExample) |
| AU (5) | AU2015266818B2 (enExample) |
| BR (1) | BR112016027805A2 (enExample) |
| CA (1) | CA2950192A1 (enExample) |
| CY (1) | CY1122790T1 (enExample) |
| DK (1) | DK3149031T3 (enExample) |
| ES (1) | ES2784237T3 (enExample) |
| HR (1) | HRP20200376T1 (enExample) |
| IL (3) | IL290655B2 (enExample) |
| LT (1) | LT3149031T (enExample) |
| MX (2) | MX375379B (enExample) |
| PL (1) | PL3149031T3 (enExample) |
| PT (1) | PT3149031T (enExample) |
| SA (1) | SA516380394B1 (enExample) |
| SI (1) | SI3149031T1 (enExample) |
| SM (1) | SMT202000143T1 (enExample) |
| WO (1) | WO2015184228A1 (enExample) |
Families Citing this family (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL290655B2 (en) * | 2014-05-29 | 2024-05-01 | Us Health | Anti-human papillomavirus 16 E7 T-cell chelates |
| WO2016179006A1 (en) * | 2015-05-01 | 2016-11-10 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of isolating t cells and t cell receptors having antigenic specificity for a cancer-specific mutation from peripheral blood |
| EP4212547A1 (en) | 2015-12-03 | 2023-07-19 | Juno Therapeutics, Inc. | Modified chimeric receptors and related compositions and methods |
| US10975436B2 (en) | 2016-01-05 | 2021-04-13 | Diamir, Llc | Methods of using miRNA from bodily fluids for diagnosis and monitoring of neurodevelopmental disorders |
| WO2017139199A1 (en) | 2016-02-10 | 2017-08-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Inducible arginase |
| KR20190054094A (ko) | 2016-09-27 | 2019-05-21 | 세로 테라퓨틱스, 인코포레이티드 | 키메라 포식작용 수용체 분자 |
| MA46354A (fr) | 2016-10-03 | 2019-08-07 | Juno Therapeutics Inc | Molécules se liant spécifiquement au vph |
| IL266892B2 (en) * | 2016-12-02 | 2025-10-01 | Univ Southern California | Artificial immune receptors and methods of using them |
| GB201700621D0 (en) | 2017-01-13 | 2017-03-01 | Guest Ryan Dominic | Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue |
| CA3062433A1 (en) * | 2017-05-15 | 2018-11-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Bicistronic chimeric antigen receptors and their uses |
| US10806780B2 (en) * | 2017-06-28 | 2020-10-20 | Regeneron Pharmaceuticals, Inc. | Anti-human papillomavirus (HPV) antigen-binding proteins and methods of use thereof |
| CN111386284B (zh) | 2017-09-26 | 2024-08-30 | 森罗治疗公司 | 嵌合吞噬受体分子和使用方法 |
| FI3688027T3 (fi) | 2017-09-29 | 2025-12-09 | Us Health | Mutatoidun p53:n tunnistavia t-solureseptoreita |
| US11952408B2 (en) * | 2017-10-03 | 2024-04-09 | Juno Therapeutics, Inc. | HPV-specific binding molecules |
| MA50748A (fr) | 2017-10-05 | 2020-08-12 | Us Health | Méthodes d'expansion sélective de cellules exprimant un tcr avec une région constante murine |
| JP2021502077A (ja) | 2017-11-06 | 2021-01-28 | エディタス・メディシン，インコーポレイテッド | 免疫療法のためのｔ細胞におけるｃｂｌｂのｃｒｉｓｐｒ−ｃａｓ９編集のための方法、組成物および構成要素 |
| WO2019139987A1 (en) | 2018-01-09 | 2019-07-18 | Elstar Therapeutics, Inc. | Calreticulin binding constructs and engineered t cells for the treatment of diseases |
| US20210052647A1 (en) | 2018-02-09 | 2021-02-25 | The United States Of America,As Represented By The Secretary,Department Of Health And Human Services | Tethered interleukin-15 and interleukin-21 |
| AU2019243154A1 (en) | 2018-03-28 | 2020-10-01 | Cero Therapeutics, Inc. | Cellular immunotherapy compositions and uses thereof |
| WO2019191334A1 (en) | 2018-03-28 | 2019-10-03 | Cero Therapeutics, Inc. | Chimeric tim4 receptors and uses thereof |
| CN112218886A (zh) * | 2018-03-28 | 2021-01-12 | 森罗治疗公司 | 嵌合吞噬受体的表达载体、基因修饰的宿主细胞及其用途 |
| KR20210020873A (ko) | 2018-04-05 | 2021-02-24 | 주노 쎄러퓨티크스 인코퍼레이티드 | 재조합 수용체를 발현하는 τ 세포, 관련 폴리뉴클레오티드 및 방법 |
| MX2020010459A (es) | 2018-04-05 | 2021-01-20 | Juno Therapeutics Inc | Metodos para producir celulas que expresan un receptor recombinante y composiciones relacionadas. |
| TWI840351B (zh) * | 2018-04-05 | 2024-05-01 | 美商奇諾治療有限公司 | T細胞受體及表現其之工程化細胞 |
| CA3097858A1 (en) | 2018-04-24 | 2019-10-31 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of producing t cell populations using hydroxycitric acid and/or a salt thereof |
| WO2019243888A1 (en) * | 2018-06-22 | 2019-12-26 | Kite Pharma Eu B.V. | Compositions and methods for making engineered t cells |
| CN112955465A (zh) | 2018-07-03 | 2021-06-11 | 马伦戈治疗公司 | 抗tcr抗体分子及其用途 |
| EP3833742A2 (en) | 2018-08-09 | 2021-06-16 | Juno Therapeutics, Inc. | Processes for generating engineered cells and compositions thereof |
| MA53612A (fr) | 2018-09-11 | 2021-09-15 | Juno Therapeutics Inc | Procédés d'analyse par spectrométrie de masse de compositions cellulaires modifiées |
| WO2020113141A2 (en) | 2018-11-30 | 2020-06-04 | Alpine Immune Sciences, Inc. | Cd86 variant immunomodulatory proteins and uses thereof |
| CN119039441A (zh) | 2019-02-21 | 2024-11-29 | 马伦戈治疗公司 | 与nkp30结合的抗体分子及其用途 |
| CN114026122B (zh) | 2019-02-21 | 2024-12-31 | 马伦戈治疗公司 | 结合t细胞相关癌细胞的多功能分子及其用途 |
| US12404331B2 (en) | 2019-04-19 | 2025-09-02 | Tcrcure Biopharma Corp. | Anti-PD-1 antibodies and uses thereof |
| BR112021021075A2 (pt) | 2019-05-01 | 2021-12-14 | Editas Medicine Inc | Células que expressam um receptor recombinante de um locus de tgfbr2 modificado, polinucleotídeos relacionados e métodos |
| CN114245745A (zh) | 2019-06-20 | 2022-03-25 | 纪念斯隆-凯特琳癌症中心 | 靶向pik3ca突变的t细胞受体及其用途 |
| BR112021026408A2 (pt) | 2019-06-27 | 2022-02-08 | Us Health | Receptores de célula t que reconhecem a mutação r175h ou y220c em p53 |
| CN110357952B (zh) * | 2019-07-17 | 2022-03-22 | 深圳市因诺转化医学研究院 | 识别人乳头瘤病毒hpv16-e7抗原的tcr |
| BR112022011795A2 (pt) | 2019-12-20 | 2022-08-30 | Instil Bio Uk Ltd | Métodos para preparar e isolar uma população terapêutica de linfócitos e para tratar câncer em um indivíduo, população terapêutica de linfócitos, bolsa criopreservada, recipiente flexível, e, sistema para extração de linfócitos |
| KR102842684B1 (ko) * | 2019-12-30 | 2025-08-05 | 브리스타 이뮤노테크 리미티드 | 향상된 t-세포 수용체 star 및 이의 적용 |
| CN116234829A (zh) | 2020-01-03 | 2023-06-06 | 马伦戈治疗公司 | 抗tcr抗体分子及其用途 |
| CN113072635B (zh) * | 2020-01-06 | 2023-08-25 | 香雪生命科学技术（广东）有限公司 | 一种识别hpv抗原的t细胞受体及其编码序列 |
| WO2021223707A1 (zh) * | 2020-05-07 | 2021-11-11 | 华夏英泰（北京）生物技术有限公司 | 改进的t细胞受体-共刺激分子嵌合物 |
| WO2021238903A1 (zh) * | 2020-05-25 | 2021-12-02 | 华夏英泰（北京）生物技术有限公司 | 增强型合成t细胞受体抗原受体 |
| WO2021252517A1 (en) * | 2020-06-09 | 2021-12-16 | Board Of Regents, The University Of Texas System | Engineered t cell receptors and methods of use |
| KR20230042283A (ko) | 2020-06-26 | 2023-03-28 | 주노 테라퓨틱스 게엠베하 | 재조합 수용체를 조건부로 발현하는 조작된 ｔ 세포, 관련된 폴리뉴클레오티드 및 방법 |
| GB2614166A (en) | 2020-09-04 | 2023-06-28 | Us Health | T cell receptors recognizing R273C or Y220C mutations in P53 |
| WO2022060904A1 (en) * | 2020-09-16 | 2022-03-24 | Obsidian Therapeutics, Inc. | Compositions and methods for expression of t-cell receptors with small molecule-regulated cd40l in t cells |
| EP4243937A2 (en) | 2020-11-13 | 2023-09-20 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Enhanced antigen reactivity of immune cells expressing a mutant non-signaling cd3 zeta chain |
| BR112023022765A2 (pt) | 2021-05-05 | 2024-01-02 | Immatics Biotechnologies Gmbh | Proteínas de ligação ao antígeno que ligam especificamente o prame |
| CN117957245A (zh) | 2021-05-07 | 2024-04-30 | 美国政府(由卫生和人类服务部的部长所代表) | 识别p53中的c135y、r175h或m237i突变的t细胞受体 |
| CN117897411A (zh) * | 2021-06-30 | 2024-04-16 | 华夏英泰（北京）生物技术有限公司 | 一种多靶点合成t细胞受体抗原/抗体受体及其应用 |
| US20240424101A1 (en) * | 2021-09-07 | 2024-12-26 | Corregene Biotechnology Co., Ltd. | Antigen binding proteins and uses thereof |
| CN118265721A (zh) * | 2021-10-18 | 2024-06-28 | 得克萨斯州大学系统董事会 | 靶向ndc80抗原的肽和经改造t细胞受体及使用方法 |
| WO2023081900A1 (en) | 2021-11-08 | 2023-05-11 | Juno Therapeutics, Inc. | Engineered t cells expressing a recombinant t cell receptor (tcr) and related systems and methods |
| CA3237646A1 (en) * | 2021-11-10 | 2023-05-19 | Tscan Therapeutics, Inc. | Binding proteins recognizing hpv16 e7 antigen and uses thereof |
| US20250154503A1 (en) | 2022-01-14 | 2025-05-15 | Tune Therapeutics, Inc. | Compositions, systems, and methods for programming t cell phenotypes through targeted gene repression |
| US20250134999A1 (en) | 2022-01-14 | 2025-05-01 | Tune Therapeutics, Inc. | Compositions, systems, and methods for programming t cell phenotypes through targeted gene activation |
| US20250243260A1 (en) | 2022-03-07 | 2025-07-31 | Alpine Immune Sciences, Inc. | Immunomodulatory proteins of variant cd80 polypeptides, cell therapies and related methods and uses |
| WO2023196884A1 (en) | 2022-04-06 | 2023-10-12 | Juno Therapeutics, Inc. | Detection assay for human papillomavirus (hpv) type 16 (hpv-16) |
| CN115286698B (zh) * | 2022-05-10 | 2023-09-01 | 广州医科大学 | 抗原短肽用于筛选治疗与hpv相关的疾病的药物中的用途及其筛选的tcr |
| CN120239746A (zh) | 2022-09-19 | 2025-07-01 | 图恩疗法股份有限公司 | 用于调节t细胞功能的组合物、系统和方法 |
| CN116731155B (zh) * | 2022-09-21 | 2024-03-22 | 新景智源生物科技(苏州)有限公司 | 人乳头瘤病毒特异性t细胞受体、表达其的细胞和其用途 |
| WO2024206274A2 (en) | 2023-03-27 | 2024-10-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T cell receptors targeting y220c or r175h mutation in p53 |
| WO2025006196A1 (en) | 2023-06-28 | 2025-01-02 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T cell receptors targeting ras with g12d, g12r, or g12v mutation |
| WO2025029840A1 (en) | 2023-07-31 | 2025-02-06 | Tune Therapeutics, Inc. | Compositions and methods for multiplexed activation and repression of t cell gene expression |
| WO2025029835A1 (en) | 2023-07-31 | 2025-02-06 | Tune Therapeutics, Inc. | Compositions and methods for modulating il-2 gene expression |
| WO2025096419A1 (en) * | 2023-10-31 | 2025-05-08 | Lyell Immunopharma, Inc. | T cells comprising a chimeric antigen receptor targeting transforming growth factor beta and a t cell receptor targeting a tumor antigen, and use thereof |
| WO2025160480A1 (en) | 2024-01-26 | 2025-07-31 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Enhanced tumor reactivity of t cells lacking sit1, lax1, or trat1 |
| WO2025193926A1 (en) | 2024-03-15 | 2025-09-18 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T cell receptors targeting e545k or n345k mutation in pik3ca |
| WO2025250587A1 (en) | 2024-05-29 | 2025-12-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Drug-regulatable, inducible cytokine expression |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| IN165717B (enExample) | 1986-08-07 | 1989-12-23 | Battelle Memorial Institute | |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| DE69133476T2 (de) | 1990-08-29 | 2006-01-05 | GenPharm International, Inc., Palo Alto | Transgene Mäuse fähig zur Produktion heterologer Antikörper |
| JP3266311B2 (ja) | 1991-05-02 | 2002-03-18 | 生化学工業株式会社 | 新規ポリペプチドおよびこれを用いる抗ｈｉｖ剤 |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| US6265150B1 (en) | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
| US5714352A (en) | 1996-03-20 | 1998-02-03 | Xenotech Incorporated | Directed switch-mediated DNA recombination |
| WO2001058479A1 (en) | 2000-02-08 | 2001-08-16 | The Penn State Research Foundation | Immunotherapy using interleukin 13 receptor subunit alpha 2 |
| WO2004021995A2 (en) | 2002-09-06 | 2004-03-18 | The Government Of The United States Of America, Represented By The Secretary, Departement Of Health And Human Services | Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy |
| WO2006103429A2 (en) * | 2005-04-01 | 2006-10-05 | Medigene Limited | High affinity hiv t cell receptors |
| PT2016102E (pt) * | 2006-05-03 | 2012-05-15 | Us Gov Health & Human Serv | Recetores de célula t quimérica e materiais relacionados e métodos de uso |
| AU2008257792B2 (en) | 2007-05-31 | 2013-08-29 | Isa Pharmaceuticals B.V. | HPV epitopes targeted by T cells infiltrating cervical malignancies for use in vaccines |
| US8383099B2 (en) | 2009-08-28 | 2013-02-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Adoptive cell therapy with young T cells |
| GB0917090D0 (en) * | 2009-09-29 | 2009-11-11 | Ucl Biomedica Plc | T-cell receptor |
| WO2012129201A1 (en) | 2011-03-22 | 2012-09-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of growing tumor infiltrating lymphocytes in gas-permeable containers |
| CA2918216C (en) * | 2013-07-15 | 2023-03-21 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-human papillomavirus 16 e6 t cell receptors |
| IL290655B2 (en) * | 2014-05-29 | 2024-05-01 | Us Health | Anti-human papillomavirus 16 E7 T-cell chelates |
-
2015
- 2015-05-29 IL IL290655A patent/IL290655B2/en unknown
- 2015-05-29 LT LTEP15729004.0T patent/LT3149031T/lt unknown
- 2015-05-29 ES ES15729004T patent/ES2784237T3/es active Active
- 2015-05-29 CN CN201580031789.XA patent/CN106661098B/zh active Active
- 2015-05-29 PL PL15729004T patent/PL3149031T3/pl unknown
- 2015-05-29 EP EP19217074.4A patent/EP3689900B1/en active Active
- 2015-05-29 WO PCT/US2015/033129 patent/WO2015184228A1/en not_active Ceased
- 2015-05-29 CA CA2950192A patent/CA2950192A1/en active Pending
- 2015-05-29 US US15/313,673 patent/US10174098B2/en active Active
- 2015-05-29 EP EP15729004.0A patent/EP3149031B1/en active Active
- 2015-05-29 KR KR1020227032043A patent/KR102618267B1/ko active Active
- 2015-05-29 SM SM20200143T patent/SMT202000143T1/it unknown
- 2015-05-29 PT PT157290040T patent/PT3149031T/pt unknown
- 2015-05-29 DK DK15729004.0T patent/DK3149031T3/da active
- 2015-05-29 SI SI201531126T patent/SI3149031T1/sl unknown
- 2015-05-29 MX MX2016015383A patent/MX375379B/es active IP Right Grant
- 2015-05-29 KR KR1020167033189A patent/KR102445667B1/ko active Active
- 2015-05-29 BR BR112016027805A patent/BR112016027805A2/pt active IP Right Grant
- 2015-05-29 AU AU2015266818A patent/AU2015266818B2/en active Active
- 2015-05-29 CN CN202110399056.9A patent/CN113150112B/zh active Active
- 2015-05-29 JP JP2017515021A patent/JP6742991B2/ja active Active
- 2015-05-29 HR HRP20200376TT patent/HRP20200376T1/hr unknown
-
2016
- 2016-11-07 IL IL248797A patent/IL248797B/en active IP Right Grant
- 2016-11-24 MX MX2020010035A patent/MX2020010035A/es unknown
- 2016-11-29 SA SA516380394A patent/SA516380394B1/ar unknown
-
2018
- 2018-11-30 US US16/205,631 patent/US10870687B2/en active Active
-
2019
- 2019-12-18 AU AU2019283892A patent/AU2019283892B2/en active Active
-
2020
- 2020-03-16 CY CY20201100238T patent/CY1122790T1/el unknown
- 2020-07-29 JP JP2020127833A patent/JP6997267B2/ja active Active
- 2020-11-23 US US17/101,360 patent/US11434272B2/en active Active
-
2021
- 2021-04-13 AU AU2021202227A patent/AU2021202227B2/en active Active
- 2021-04-21 IL IL282518A patent/IL282518B/en unknown
- 2021-12-16 JP JP2021203953A patent/JP7291196B2/ja active Active
-
2022
- 2022-08-01 US US17/816,496 patent/US20220372103A1/en active Pending
-
2023
- 2023-02-06 AU AU2023200608A patent/AU2023200608B2/en active Active
- 2023-06-02 JP JP2023091878A patent/JP7535158B2/ja active Active
-
2024
- 2024-08-02 JP JP2024126652A patent/JP7744479B2/ja active Active
- 2024-11-19 AU AU2024266702A patent/AU2024266702A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017524372A5 (enExample) | ||
| Saunders et al. | Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses | |
| Abd Ellah et al. | Nanomedicine as a promising approach for diagnosis, treatment and prophylaxis against COVID-19 | |
| JP2016527230A5 (enExample) | ||
| Davidson et al. | Effect of TA-CIN (HPV 16 L2E6E7) booster immunisation in vulval intraepithelial neoplasia patients previously vaccinated with TA-HPV (vaccinia virus encoding HPV 16/18 E6E7) | |
| Baldwin et al. | Vaccinia-expressed human papillomavirus 16 and 18 e6 and e7 as a therapeutic vaccination for vulval and vaginal intraepithelial neoplasia | |
| Brun et al. | Regression of high-grade cervical intraepithelial neoplasia with TG4001 targeted immunotherapy | |
| Srivastava et al. | CXCL17 chemokine–dependent mobilization of CXCR8+ CD8+ effector memory and tissue-resident memory T cells in the vaginal mucosa is associated with protection against genital herpes | |
| HRP20200376T1 (hr) | Receptori t-stanica protiv ljudskog papiloma virusa 16e7 | |
| US11524063B2 (en) | Materials and methods relating to immunogenic epitopes from human papillomavirus | |
| Gao et al. | Immune response to human papillomavirus type 16 E6 gene in a live vaccinia vector | |
| Zhang et al. | Targeting the genital tract mucosa with a lipopeptide/recombinant adenovirus prime/boost vaccine induces potent and long-lasting CD8+ T cell immunity against herpes: importance of MyD88 | |
| JP2018535647A5 (enExample) | ||
| JPH0372430A (ja) | 細胞間粘着分子の官能性誘導体を用いた抗ウィルス剤 | |
| Zheng et al. | A novel neutralizing antibody specific to the DE loop of VP1 can inhibit EV-D68 infection in mice | |
| Backes et al. | Maternally transferred mAbs protect neonatal mice from HSV-induced mortality and morbidity | |
| CN111378048A (zh) | 针对中东呼吸综合征冠状病毒的抗体-多肽双特异性免疫治疗剂 | |
| EP3677677A1 (en) | Anti-hsv gb monoclonal antibody or antigen-binding fragment thereof | |
| Mattil-Fritz et al. | Immunotherapy of equine sarcoid: dose-escalation trial for the use of chimeric papillomavirus-like particles | |
| Cheng et al. | Clinical application of antibody immunity against SARS-CoV-2: comprehensive review on immunoassay and immunotherapy | |
| Dhanushkodi et al. | Mucosal CCL28 Chemokine Improves Protection against Genital Herpes through Mobilization of Antiviral Effector Memory CCR10+ CD44+ CD62L− CD8+ T Cells and Memory CCR10+ B220+ CD27+ B Cells into the Infected Vaginal Mucosa | |
| CN101153059B (zh) | 用于鼻咽癌筛查、诊断和治疗效果预测的elisa试剂盒 | |
| Afshar Moghaddam et al. | Recent advances in treatment and detection of Rift Valley fever virus: a comprehensive overview | |
| Yhee et al. | Characterization of canine oral papillomavirus by histopathological and genetic analysis in Korea | |
| Sauter et al. | Role of the capsid protein VP4 in the plasma-dependent enhancement of the Coxsackievirus B4E2-infection of human peripheral blood cells |